ArticleInternational journal of endocrinology2026
Effect of Polyethylene Glycol Loxenatide Treatment on Body Weight in Patients With Type 2 Diabetes With Different Body Mass Index: A Retrospective Real-World Study.
Article in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Real-world data on the effect of polyethylene glycol loxenatide (PEG-Loxe) in patients with Type 2 diabetes mellitus (T2DM) with normal body mass index (BMI) are lacking. Therefore, this study aims to observe the effect of PEG-Loxe on the weight of patients with T2DM with different BMIs. Methods: This single-center, retrospective real-world study included patients with T2DM, aged ≥ 18 years, and receiving PEG-Loxe/sodium-glucose cotransporter 2 inhibitor (SGLT2i). The primary endpoint was change in body weight after 24 weeks of treatment. Secondary endpoints included proportion of patients with body weight reduction < 5.0% and < 10%, changes in BMI, and glycosylated hemoglobin (HbA1c). Results: Overall, 487 patients treated with SGLT2i or PEG-Loxe were identified; after propensity score matching, 68 patients were included in each group. After 24 weeks, the mean change in body weight and BMI was -1.2 (-2.3, -0.1) and -0.4 (-0.8, -0.1) in the PEG-Loxe group and -2.4 (-3.5, -1.3) and -0.7 (-1.1, -0.4) in the SGLT2i group. A ≥ 5% and ≥ 10% weight loss was noted by 32.4% and 8.8% of patients in the PEG-Loxe group, with a mean change in HbA1c (%) of -1.48 (-1.98, -0.99). Weight loss (≥ 5%) in obese patients (BMI > 28 kg/m Conclusion: PEG-Loxe resulted in weight loss and glycemic control in patients with T2DM. The weight loss was negatively correlated with baseline BMI without excessive weight loss in normal BMI, supporting PEG-Loxe's use in this group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.